Drug Approval | May 11, 2024
Strides receives USFDA approval for Sevelamer Carbonate Tablets
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
The company is committed to address this observation comprehensively within stipulated time
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
With this, for all our USFDA facilities, EIRs are in place
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
